Lupin Q2 results update

Last updated: 05 Nov, 2020 | 11:12 am

Lupin Q2 results update

Earnings meets estimates: Lupin has reported a net profit of ₹211.02 crore in Q2FY21, compared to a net loss of Rs 127.07 crore during the same period last year. The company’s profit recovered mainly due to a rebound in its US business. The profit grew 97% on a QoQ basis.  

Revenue declines marginally: Consolidated total revenue from operations of the company stood at Rs 3,835 crore for the Jul-Sep period, a decline of 1.2% on-year.The decline was mainly due to a decline in India sales, which is the second-largest market after US making up 35% of the total sales. India sales saw a decline of 0.7% drop on year to ₹1,323.30 crore. Lupin is now the 6 th largest company in the Indian Pharmaceutical Market. The chart below shows Lupin’s sales mix. 

Margins improve: Lupin’s EBITDA margin grew by 10 bps to 16.8% in the quarter. The EBITDA declined 21.1% on-year to ₹606.1 crore. The Company launched 7 products during the quarter in the US market and now has 181 products in the US generics market. Lupin is now the market leader for 62 products in the US generics market. 

Management commentary: “We are very pleased with the strong recovery of our business during the quarter, demonstrated by sequential growth across all our geographies, in particular US and India,' Lupin said. 

Lupin was able to turn in a profit in the quarter, aided by a recovery in its US business. Revenues in the North America market, which has grown 5.6% on-year. This makes up 37% of total sales.The company expects to sustain the momentum on margin improvement led by optimisation efforts underway and strong growth in its key businesses.

Finzoom Investment Advisors Private Limited (Brand Name - INDmoney, INDwealth,,, makes no warranties or representations, express or implied, on products and services offered through the platform. It accepts no liability for any damages or losses, however, caused in connection with the use of, or on the reliance of its advisory or related services.

Past performance is not indicative of future returns. Please consider your specific investment requirements, risk tolerance, goal, time frame, risk and reward balance and the cost associated with the investment before choosing a fund, or designing a portfolio that suits your needs. Performance and returns of any investment portfolio can neither be predicted nor guaranteed.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Marketing and distribution of various financial products such as loans and deposits are powered by Finzoomers Services Private Limited.

INDmoney, INDwealth, are brand and product of Finzoom Investment Advisors (P) Limited.

© Finzoom Investment Advisors Private Limited

[SEBI RIA Registration No: INA100012190] [Type of Registration: Non-Individual] [Validity of registration: December 17, 2018-Perpetual] [Address: 616, 6th Floor, Suncity Success Tower, Golf Course Extension Road, Sector – 65, Gurugram, Haryana- 122005] [Principal Officer details: Mr. Gaurav Sharma, Email id:, Contact No. 8800826254] [Corresponding SEBI local office address: Securities and Exchange Board of India, Local Office, First Floor, SCO 127-128, Sector 17C, Chandigarh-160017]

[ARN - 151913] [Platform Partner : BSE (Member code-24801)] [CIN - U67190HR2018PTC073294] [GST No : 06AADCF3538Q1Z8]